PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief
PainReform Ltd. (Nasdaq: PRFX) reported in vitro test results comparing its lead product, PRF-110, with the industry leader as a topical analgesia for postoperative pain relief. PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading, including a greater ability to spread evenly due to its viscosity (PRF-110 1,500 cP vs. industry leader 3,000 cP).
The recent in vitro results reported by PainReform Ltd. concerning their lead product, PRF-110, highlight a significant advancement in the pharmaceutical field of postoperative pain management. The reported superior surface-tissue spreading properties of PRF-110, when compared to the industry leader, could potentially translate into more effective and efficient drug delivery. This efficacy is derived from the product's viscosity, which appears to be optimized for even distribution over the affected area.
From a pharmacokinetic standpoint, the ability of a topical analgesic to spread evenly is crucial as it could ensure a consistent and prolonged therapeutic effect, potentially reducing the need for additional analgesic administration. If these in vitro results can be replicated in vivo, PRF-110 may offer a competitive advantage in the postoperative pain relief market, which is a segment with a substantial patient population. However, it is important to note that in vitro results do not always correlate with clinical outcomes and further studies will be required to confirm the efficacy and safety profile of PRF-110 in patients.
The report of PRF-110's enhanced formulation properties could have a positive impact on PainReform's market positioning and investor sentiment. The postoperative pain management market is a growing sector due to the increasing number of surgeries performed globally and the rising awareness of the need for effective pain control. A product that offers improved performance over existing market leaders can capture a significant market share, especially if it leads to better patient outcomes and potential cost savings for healthcare providers.
Investors should monitor the progress of PRF-110 through clinical trials and regulatory pathways, as successful outcomes could lead to substantial growth in PainReform's valuation. Additionally, partnerships or licensing deals may become more likely if PRF-110's benefits are clinically validated. The market will also be looking for signs of intellectual property protection for PRF-110, as this would provide a competitive moat and could justify a premium valuation for PainReform.
The in vitro test results of PRF-110 provide a promising outlook for the drug's performance in a clinical setting. The focus on surface-tissue spreading is a critical factor in the effectiveness of topical analgesics. The viscosity of 1,500 centipoise (cP) suggests a formulation that is neither too fluid nor too rigid, which could facilitate optimal absorption and retention at the site of application.
For stakeholders, the transition from in vitro to clinical trials will be pivotal. The next steps would likely include Phase I/II studies to assess the safety, tolerability and preliminary efficacy of PRF-110 in humans. Success in these trials could result in substantial interest from larger pharmaceutical entities seeking to diversify their pain management portfolios. Conversely, any negative outcomes could significantly impact PainReform's stock performance and investment outlook. Thus, while the in vitro results are promising, they are merely the first step in a rigorous process of drug development and commercialization.
01/03/2024 - 08:30 AM
PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading
TEL AVIV, Israel, Jan. 03, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd PainReform " or the "Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today reported in vitro test results comparing the Company’s lead product, PRF-110, versus the industry leader, as a topical analgesia for postoperative pain relief.
The in vitro tests were designed to mimic the spreadability attribute critically required for post-surgical topical applications. PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading, including a greater ability to spread evenly due to its viscosity (PRF-110 1,500 cP vs. about 10,000 cP for commercial competitor), and superior surface interaction with surgical tissue based on a slide test, which demonstrated sliding of the formulations down inclined, dry and wet surfaces. In phosphate-buffered saline, the sliding of PRF-110 was twice that of the competitor.
Ilan Hadar, Chief Executive Officer of PainReform, stated, “We are encouraged by these results, which further demonstrate that PRF-110, our long-acting ropivacaine formulation, provides unique and significant benefits for local administration in postoperative pain management. PRF-110 clearly excelled in terms of surface/tissue spreading and staying in place—a key advantage in achieving effective post-surgical pain relief—as it is critical to have even distribution inside the surgical wound. Additionally, PRF-110 is manufactured via a scalable and cost-effective process, is easy to commercialize, and contains excipients that are all FDA-approved as GRAS (generally regarded as safe). As a result, we could not be more encouraged by the outlook for PRF-110 as we advance the current second part of our Phase 3 clinical trial.”
Earlier this year, the Company completed the first part of its Phase 3 clinical trial of PRF-110, in which 15 patients undergoing bunionectomy surgery were enrolled at two clinical sites in Texas. PRF 110 was well tolerated, all adverse events were mild, and no serious adverse events were observed, suggesting a substantial potential advantage to using PRF-110 over opioids. The second part of the trial, currently underway, is a double-blind study, randomizing approximately 400 patients at six clinical sites in the U.S. and measuring pain reduction by PRF-110 over 72 hours compared with placebo.
About PainReform
PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product is based on the local anesthetic ropivacaine, targeting the postoperative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended postoperative analgesia. The Company's proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. For more information, please visit www.painreform.com .
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements about our expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward- looking statements, including, but not limited to, the following: our history of significant losses, our need to raise additional capital and our ability to obtain additional capital on acceptable terms, or at all; our dependence on the success of our initial product candidate, PRF-110; the outcomes of preclinical studies, clinical trials and other research regarding PRF-110 and future product candidates; our limited experience managing clinical trials; our ability to retain key personnel and recruit additional employees; our reliance on third parties for the conduct of clinical trials, product manufacturing and development; the impact of competition and new technologies; our ability to comply with regulatory requirements relating to the development and marketing of our product candidates; commercial success and market acceptance of our product candidates; our ability to establish sales and marketing capabilities or enter into agreements with third parties and our reliance on third party distributors and resellers; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights and our ability to operate our business without infringing the intellectual property rights of others; the overall global economic environment; our ability to develop an active trading market for our ordinary shares and whether the market price of our ordinary shares is volatile; and statements as to the impact of the political and security situation in Israel on our business. More detailed information about the risks and uncertainties affecting us is contained under the heading "Risk Factors" included in the Company's most recent Annual Report on Form 20-F and in other filings that we have made and may make with the Securities and Exchange Commission in the future.
Contact:
Crescendo Communications, LLCprfx@crescendo-ir.com
Ilan Hadarihadar@painreform.com
What did PainReform report about PRF-110?
PainReform reported in vitro test results comparing PRF-110 with the industry leader as a topical analgesia for postoperative pain relief. PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading.
What are the formulation properties demonstrated by PRF-110?
PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading, including a greater ability to spread evenly due to its viscosity (PRF-110 1,500 cP vs. industry leader 3,000 cP).
What is the ticker symbol for PainReform Ltd.?
The ticker symbol for PainReform Ltd. is PRFX.
What is the specialty of PainReform Ltd.?
PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics.
